Literature DB >> 23863562

Nasopharyngeal carcinoma incidence and mortality in China in 2009.

Zhi-Jian Xu1, Rong-Shou Zheng, Si-Wei Zhang, Xiao-Nong Zou, Wan-Qing Chen.   

Abstract

Nasopharyngeal carcinoma (NPC) is rare globally but common in China and exhibits a distinct ethnic and geographic distribution. In 2009, the National Central Cancer Registry in China provided real-time surveillance information on NPC. Individual NPC cases were retrieved from the national database based on the ICD-10 topography code C11. The crude incidence and mortality of NPC were calculated by sex and location (urban/rural). China's population in 1982 and Segi's world population structures were used to determine age-standardized rates. In regions covered by the cancer registries in 2009, the crude incidence of NPC was 3.61/100,000 (5.08/100,000 in males and 2.10/100,000 in females; 4.19/100,000 in urban areas and 2.42/100,000 in rural areas). Age-standardized incidences by Chinese population (ASIC) and Segi's world population (ASIW) were 2.05/100,000 and 2.54/100,000, respectively. The crude mortality of NPC was 1.99/100,000 (2.82/100,000 in males and 1.14/100,000 in females; 2.30/100,000 in urban areas and 1.37/100,000 in rural areas). The age-standardized mortalities by Chinese population (ASMC) and world population (ASMW) were 1.04/100,000 and 1.35/100,000, respectively. The incidence and mortality of NPC were higher in males than in females and higher in urban areas than in rural areas. Both age-specific incidence and mortality were relatively low in persons younger than 30 years old, but these rates dramatically increased. Incidence peaked in the 60-64 age group and mortality peaked in the over 85 age group. Primary and secondary prevention, such as lifestyle changes and early detection, should be carried out in males and females older than 30 years of age.

Entities:  

Mesh:

Year:  2013        PMID: 23863562      PMCID: PMC3845582          DOI: 10.5732/cjc.013.10118

Source DB:  PubMed          Journal:  Chin J Cancer        ISSN: 1944-446X


Nasopharyngeal carcinoma (NPC) is a rare malignancy in most parts of the world but is particularly frequent in China, especially in the South[1]. The average incidence of NPC worldwide is less than 1/100,000 population[2]. However, in endemic areas of China, its incidence reaches 20/100,000[3]–[5]. In the past three decades, NPC incidence has declined among the Chinese residing in Southeast Asia, including Taiwan, Hong Kong, and Singapore[5]—areas with lifestyles distinct from that of mainland China. The National Central Cancer Registry (NCCR) of China, responsible for data collection, evaluation, analysis, and publication from population-based cancer registries, has organized three retrospective mortality surveys on the causes of cancer death, which provide sex- and age-specific mortality for major cancers among areas in mainland China. Recent population-based studies in China show that the incidence of NPC in some areas has remained stable in males and even slightly decreased in females[6],[7]. Additionally, although rates are still higher in persons over 50 years of age, the age-specific mortality in the high risk age group has followed a downward trend over a 30-year period. The NCCR of China established the Chinese Cancer Registry annual report system to comprehensively promote cancer registration. The Chinese Cancer Registry Annual Report has been published since 2008 and has provided the scientific basis for cancer prevention and control in China. In 2012, the NCCR collected data for the calendar year 2009 from 104 registries. After comprehensive quality evaluation, data from 72 registries were selected as sources of the annual report to reflect cancer incidence and mortality in the registration areas. In this study, NPC cases were retrieved from the national database for analysis to show the updated NPC burden in Chinese population.

Materials and Methods

Data source

All new cancer cases diagnosed in 2009 were reported to cancer registries from all hospitals, community health centers, and other institutions, including centers of township medical insurance and the New-type Rural Cooperative Medical System. The death record database was linked and matched with the cancer registration database for identifying cancer deaths and missed cases. Totally 104 cancer registries (covering 46 cities and 58 counties in 27 provinces) reported cancer registration data to NCCR. The overall population coverage was 109,476,347, accounting for 8.2% of the whole population. The cancer registries coded cancer site and histology according to the International Classification of Diseases for Oncology, third edition (ICD-03) and tenth edition (ICD-10). Invasive cases of NPC (topography code C11) were retrieved and analyzed from the overall cancer database. Demographic information was provided by the National Statistics Bureau.

Quality control

Based on the guideline of Chinese cancer registration[8] and the standard of data inclusion in Cancer Incidence in Five Continents Volume IX[9], cancer registration data were evaluated by several quality indicators: proportion of morphologic verification (MV%), percentage of cancer cases identified with death certification only (DCO%), and mortality/incidence ratio (M/I)[10]–[12]. The detailed standard for data inclusion was shown previously[13]. Generally, data with DCO% less than 20%, an overall MV% more than 55%, and M/I between 0.55 and 0.95 were considered acceptable.

Statistical analysis

Crude incidence and mortality of NPC were prepared by sex, area, and 19 total age groups (<1, 1–4, 5–9,…80–84, ≥85 years). Age-standardized rates were calculated using the Chinese population from 1982 and Segi's World population. The cumulative risk of developing or dying from cancer for persons young than 75 years (in the absence of competing causes of death) was calculated and presented as a percentage. Software including MS-FoxPro, MS-Excel, and IARCcrgTools issued by the International Agency for Research on Cancer (IARC) and the International Association of Cancer Registration (IACR) were used for data checkup. SAS software (version 9.0) was used to calculate incidence and mortality.

Results

Pooled data

After evaluating all submitted information, data from 72 population-based cancer registries were accepted for the annual report. The population covered by these cancer registries was 85,470,522, including 43,231,554 males and 42,238,968 females, accounting for 6.4% of the whole population. A total of 31 registries were from urban areas, covering a total population of 57,489,009, whereas 41 registries were from rural areas, covering a total population of 27,981,513. The MV%, DCO%, and M/I for the national pooled data were 71.99%, 3.05%, and 0.55, respectively, in urban areas and 70.65%, 3.54%, and 0.56, respectively, in rural areas. There were 3,085 new cases of NPC (2,197 males and 888 females) and 1,702 overall NPC cancer deaths (1,219 males and 483 females) in 2009. Detailed information for the covered population, including NPC incidence and deaths in each cancer registry, is shown in .
Table 1.

Population and number of new nasopharyngeal carcinoma (NPC) cases and deaths in cancer registries in 2009

RegistryAreaaPopulation
New NPC cases
NPC deaths
BothMalesFemalesBothMalesFemalesBothMalesFemales
Beijing17,645,1863,859,5863,785,600816417765620
Qianxi2361,312182,138179,174110000
Shexian2394,944205,168189,776220220
Cixian2634,333322,621311,712651220
Baoding1948,612478,051470,5611156422
Yangquan1683,165346,023337,142220211
Yangcheng2383,165192,119191,046532202
Chifeng11,203,006613,725589,2811064743
Shenyang13,497,8151,722,9761,774,839564115341915
Dalian12,266,2241,136,7721,129,45236261018144
Zhuanghe2915,660461,826453,83415114514
An'shan11,471,775731,916739,8592214814104
Benxi1955,409475,113480,29613112651
Dandong1767,011378,794388,21714861055
Donggang2640,853323,798317,05522184321
Dehui2943,395479,486463,90921174853
Yanji2440,957215,260225,697000211
Daoli District, Harbin1713,264351,071362,19312102651
Nangang District, Harbin11,020,233508,921511,31213941082
Shangzhi2616,046314,864301,182303000
Shanghai16,181,3343,084,4963,096,8382201675318915237
Jintan2545,00026,2407282,59311741183
Suzhou12,392,0871,183,7161,208,371795524513714
Haian2936,785463,612473,173161061697
Qidong21,114,951548,805566,14638251325178
Haimen21,016,228501,407514,82132181413112
Lianyungang1886,862452,358434,504161241064
Donghai21,117,858579,751538,10717981192
Guanyun21,015,229534,502480,7271913616142
Chuzhou District, Huai'an11,174,877609,088565,78914951174
Huaiyin District, Huai'an1900,027465,502434,52513103202
Xuyi2759,450388,180371,27029209743
Jinhu2352,292176,689175,6031192541
Sheyang2965,817494,682471,135241861596
Jianhu2805,465410,369395,096972972
Dafeng2724,147363,326360,8211174743
Yangzhong2272,046134,758137,288981220
Taixing21,128,840613,199515,641171251073
Hangzhou16,753,5093,403,8933,349,6163632401231108030
Jiaxing1509,367253,819255,548161421284
Jiashan2382,475189,692192,783151231082
Haining2653,957322,969330,98831229871
Shangyu2771,321383,462387,8592117416151
Xianju2490,070255,438234,63214122761
Feixi2858,895449,882409,01318144862
Maanshan1633,477323,834309,643352411642
Tongling1433,545221,375212,170862550
Changle2673,717355,091318,6262117414131
Xiamen11,160,135583,873576,26289632626197
Zhanggong District, Ganzhou1420,759212,159208,60030181214104
Linqu2817,857417,434400,423770541
Wenshang2762,828388,454374,374321101
Feicheng2733,501358,739374,762624743
Yanshi2602,266306,192296,074110211
Linzhou2108,0241557,392522,849303330
Xiping2858,002434,899423,103642101
Wuhan14,832,1742,484,6222,347,55217312251987325
Yunmeng2524,801261,237263,56413103871
Hengdong2713,458373,923339,5353323101376
Guangzhou13,968,2162,014,5801953,636662480182374267107
Sihui2413,363211,351202,0121227943795326
Zhongshan11,468,391732,333736,058263189741399148
Liuzhou11,038,208533,050505,158685216423012
Fusui2444,332236,000208,3321915412111
Jiulongpo District, Chongqing1798,618402,961395,6572521412102
Qingyang District, Chengdu1534,701277,154257,547292541284
Ziliujing District, Zigong1357,600179,873177,72714113422
Yanting2610,103316,499293,604201281385
Jingtai2233,609119,953113,656211211
Liangzhou District, Wuwei1990,583524,276466,3071055844
Xining1882,839439,175443,6641064844
Xinyuan2271,944138,895133,049523211
Total85,470,52243,231,55442,238,9683,0852,1978881,7021,219483

a 1, urban area; 2, rural area.

a 1, urban area; 2, rural area. ASIC, age-standardized incidence by Chinese population; ASIW, age-standardized incidence by world population.

Incidence

The crude incidence of NPC was 3.61/100,000 in 2009, accounting for 1.26% of all new cancer cases. The age-standardized incidences by Chinese population (ASIC) and world population (ASIW) were 2.05/100,000 and 2.54/100,000, respectively. Among persons under the age of 75, the cumulative incidence was 0.28%. NPC occurred more frequently among males than females. For males, the crude incidence of NPC was 5.08/100,000, whereas the ASIC and ASIW were 2.89/100,000 and 3.60/100,000, respectively. For females, the crude incidence of NPC was 2.10/100,000, whereas the ASIC and ASIW were 1.21/100,000 and 1.47/100,000, respectively. The crude incidence in urban areas (4.19/100,000) was higher than that in rural areas (2.42/100,000). After age standardization, incidence in urban areas was still higher than that in rural areas (ASIW, 2.88/100,000 vs. 1.80/100,000; ).
Table 2.

NPC incidence by sex and area in regions covered by the cancer registries in 2009

LocationSexNo. of casesCrude rate (1/105)RatioASIC (1/105)ASIW (1/105)Cumulative rate (%)Age 0–74
All areasBoth3,0853.611.262.052.540.28
Males2,1975.081.602.893.600.40
Females8882.100.831.211.470.16
UrbanBoth2,4074.191.382.332.880.32
Males1,7255.951.803.324.120.46
Females6822.390.871.351.650.18
RuralBoth6782.420.971.441.800.19
Males4723.311.131.972.480.28
Females2061.500.730.901.090.11

ASIC, age-standardized incidence by Chinese population; ASIW, age-standardized incidence by world population.

Age-specific incidence of NPC for both sexes and areas was compared. Overall, the age-specific incidence was relatively low in persons under 30 years old but dramatically increased in those over 30 years old, peaking in the 60–64 age group in males and urban areas, in 80-84 age group in rural areas, and in 70-74 age group in females. For persons over 30 years old, NPC age-specific incidence was more than 2-fold greater in males than in females, although there were slight differences among those under 30 years old. The age-specific incidence of NPC in urban areas was generally higher than that in rural areas both in males and females, especially in older age groups (, ).
Table 3.

Age-specific incidence of NPC in regions covered by the cancer registries in 2009 (1/105)

Age groupAll areas
Urban areas
Rural areas
BothMalesFemalesBothMalesFemalesBothMalesFemales
All3.615.082.104.195.952.392.423.311.50
<10.160.000.340.260.000.550.000.000.00
1-40.000.000.000.000.000.000.000.000.00
5-90.060.050.060.090.090.100.000.000.00
10-140.040.040.050.040.070.000.050.000.11
15-190.180.180.190.200.220.170.160.100.22
20-240.380.370.390.370.370.360.420.370.47
25-290.610.540.680.720.700.730.360.180.55
30-341.632.330.911.982.871.080.971.340.60
35-393.234.471.983.695.062.302.323.311.32
40-444.386.022.705.107.302.852.933.472.37
45-495.898.523.166.9910.233.613.414.632.15
50-546.739.673.707.5510.904.124.656.582.62
55-597.6711.413.918.0911.964.276.6710.133.04
60-648.6312.754.509.7514.575.036.218.953.32
65-697.7311.114.428.9612.335.755.278.781.65
70-748.2712.344.549.5014.445.035.327.423.30
75-797.2010.714.097.9511.804.505.267.813.04
80-846.429.474.006.099.713.167.248.846.04
≥855.798.044.365.348.343.386.967.206.82
Figure 1.

Age-specific incidence of nasopharyngeal carcinoma (NPC) in males and females in urban and rural areas in 2009.

The age-specific incidence increased as age increased and peaked in the 60-64 age group in urban males, in the 55-59 age group in rural males, in the 65-69 age group in urban females, and in the 85 and over age group in rural females. Incidences in urban areas were higher than those in rural areas except among females over the age of 75, and incidences in males were higher than those in females in any age group.

Age-specific incidence of nasopharyngeal carcinoma (NPC) in males and females in urban and rural areas in 2009.

The age-specific incidence increased as age increased and peaked in the 60-64 age group in urban males, in the 55-59 age group in rural males, in the 65-69 age group in urban females, and in the 85 and over age group in rural females. Incidences in urban areas were higher than those in rural areas except among females over the age of 75, and incidences in males were higher than those in females in any age group.

Mortality

The mortality of NPC was higher in males than in females. The crude mortality, the age-standardized mortalities by Chinese population (ASMC) and world population (ASMW) were 2.82/100,000, 1.51/100,000, and 1.97/100,000, respectively, for males and 1.14/100,000, 0.57/100,000, and 0.74/100,000, respectively, for females. These values were 2.30/100,000, 1.15/100,000, and 1.50/100,000, respectively, in urban areas and 1.37/100,000, 0.78/100,000, and 1.00/100,000, respectively, in rural areas. NPC was confirmed to be a fatal disease in both males and females, and in urban and rural areas ().
Table 4.

NPC mortality by sex and area in regions covered by the cancer registries in 2009

LocationSexNo. of casesCrude rate (1/105)RatioASMC (1/105)ASMW (1/105)Cumulative rate (%) Age 0-74
All areasBoth1,7021.991.101.041.350.15
Males1,2192.821.261.511.970.22
Females4831.140.840.570.740.09
UrbanBoth1,3202.301.261.151.500.17
Males9463.261.461.692.210.25
Females3741.310.940.630.820.10
RuralBoth3821.370.770.781.000.11
Males2731.920.851.121.420.17
Females1090.790.620.430.560.06

ASMC, age-standardized mortality by Chinese population; ASMW, age-standardized mortality by world population.

Age-specific mortality by sex and area is shown in and . The mortality was relatively low in age groups under 40 years old and peaked in the over 85 year age group. However, in urban females, the mortality in the 75–79 age group was the highest among all groups and in rural males, the 70–74 age group had the highest mortality of NPC. The age-specific mortality of NPC in urban areas was generally higher than that in rural areas in both males and females.
Table 5.

Age-specific mortality of NPC in regions covered by the cancer registries in 2009 (1/105)

Age groupAll areas
Urban areas
Rural areas
BothMalesFemalesBothMalesFemalesBothMalesFemales
All1.992.821.142.303.261.311.371.920.79
<10.000.000.000.000.000.000.000.000.00
1-40.000.000.000.000.000.000.000.000.00
5-90.000.000.000.000.000.000.000.000.00
10-140.040.080.000.040.070.000.050.100.00
15-190.060.070.040.030.060.000.110.100.11
20-240.070.050.080.060.070.040.090.000.19
25-290.110.190.030.160.270.040.000.000.00
30-340.380.540.210.400.600.190.340.420.26
35-390.971.360.581.111.630.580.690.810.58
40-441.602.171.011.692.231.131.422.060.76
45-492.433.501.332.713.921.441.822.531.08
50-543.275.011.473.485.301.622.724.291.09
55-594.166.321.984.426.612.263.525.671.27
60-645.087.852.306.059.662.512.994.081.82
65-695.667.483.896.628.574.763.755.392.06
70-746.909.714.327.7210.585.144.937.692.29
75-798.1611.465.239.1412.995.695.627.424.06
80-847.2210.484.648.4611.935.644.096.632.20
≥858.7515.704.369.4419.293.056.965.767.67
Figure 2.

Age-specific mortality of NPC in cancer registration areas in 2009.

The age-specific mortality increased as age increased. However, a decline was observed starting in the 70-74 age group in rural males and the 80-84 age group in urban females. Mortalities in urban areas were higher than those in rural areas except among females over 85 years of age, and mortalites in males were higher than those in females in any age group.

ASMC, age-standardized mortality by Chinese population; ASMW, age-standardized mortality by world population.

Age-specific mortality of NPC in cancer registration areas in 2009.

The age-specific mortality increased as age increased. However, a decline was observed starting in the 70-74 age group in rural males and the 80-84 age group in urban females. Mortalities in urban areas were higher than those in rural areas except among females over 85 years of age, and mortalites in males were higher than those in females in any age group.

Discussion

For this analysis of NPC incidence and mortality in 2009, 72 registries were qualified as sources of the annual report on cancer burden in 2009. The data in this report covered 85.47 million people (about 57.49 million from 31 urban areas), which is the largest population coverage to date. We analyzed NPC cases including 3,085 newly diagnosed patients and 1,702 deaths—data that might be representative of the whole country. Compared with other studies in China during past decades, the incidence of NPC has remained stable[14] or slightly decreased[7] in females in low-risk regions, or has slightly increased in males in some high-risk regions[15]. NCCR data analysis revealed that the crude incidence and mortality fluctuated slightly in 2009 due to different population coverage. Additionally, NCCR results showed that incidence was higher in males than in females. The crude incidence in urban areas was also slightly higher than that in rural areas for both males and females. After age standardization, incidences were still higher in males and in urban areas compared to females and rural areas, respectively. The results showed that the age-specific incidence of persons in the 60–64 year old age group in urban areas was 1–2 times higher than that in rural areas, both in males and females. Although a rare disease worldwide, NPC shows a relatively high incidence among the Chinese, probably because of Epstein-Barr virus (EBV) infection, lifestyle, or smoking-related factors[16]. In endemic areas in China, NPC remains a common and fatal disease. The prevention strategy in China focuses mainly on secondary prevention, with a goal of improving rates of early detection and diagnosis in NPC patients and thereby giving high-risk populations a clinically valuable survival advantage[17]. Since the 1970s, NPC screening tests and studies for high-risk areas in southern China, such as Sihui, have included monitoring for EBV using anti-EBV serum biomarkers[18]–[22], but there is still no confirmed screening scheme for a larger sample size nationwide. Nevertheless, screening for plasma EBV DNA[22] in persons in high-risk age ranges[6], [19], as well as health education and promotion should become standard practice for high-risk areas in China. In conclusion, although the incidence of NPC remains stable and low in most age groups, especially in the young generation, it is still a major public issue in high-risk regions in China, especially among persons in high-risk age ranges. The cancer registry provides timely and dynamic information for making national, regional, and local policies for cancer control. As NCCR continues to expand the national cancer registry system, primary and secondary prevention of NPC is expected to improve.
  17 in total

1.  Time trends and age-period-cohort analyses on incidence rates of nasopharyngeal carcinoma during 1993-2007 in Wuhan, China.

Authors:  Shao-Hua Xie; Jie Gong; Nian-Nian Yang; Lap-Ah Tse; Ya-Qiong Yan; Ignatius Tak-Sun Yu
Journal:  Cancer Epidemiol       Date:  2011-08-16       Impact factor: 2.984

2.  Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program.

Authors:  K C Allen Chan; Emily C W Hung; John K S Woo; Paul K S Chan; Sing-Fai Leung; Franco P T Lai; Anita S M Cheng; Sze Wan Yeung; Yin Wah Chan; Teresa K C Tsui; Jeffrey S S Kwok; Ann D King; Anthony T C Chan; Andrew C van Hasselt; Y M Dennis Lo
Journal:  Cancer       Date:  2013-02-21       Impact factor: 6.860

3.  [Cost-effectiveness evaluation of seven screening strategies for nasopharyngeal carcinoma].

Authors:  Dong-ping Rao; Qing Liu; Su-mei Cao
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2012-07

4.  Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990.

Authors:  R J Black; F Bray; J Ferlay; D M Parkin
Journal:  Eur J Cancer       Date:  1997-06       Impact factor: 9.162

5.  Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.

Authors:  Yue Liu; Qihong Huang; Wanli Liu; Qing Liu; Weihua Jia; Ellen Chang; Feng Chen; Zhiwei Liu; Xiang Guo; Haoyuan Mo; Jinou Chen; Dongping Rao; Weimin Ye; Sumei Cao; Minghuang Hong
Journal:  Int J Cancer       Date:  2011-11-19       Impact factor: 7.396

Review 6.  The enigmatic epidemiology of nasopharyngeal carcinoma.

Authors:  Ellen T Chang; Hans-Olov Adami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-10       Impact factor: 4.254

7.  Interval cancers in nasopharyngeal carcinoma screening: comparing two screening intervals after a negative initial screening result.

Authors:  Feng Chen; Qi-Hong Huang; Fang Fang; Zhi-Wei Liu; Ke Liu; Shang-Hang Xie; Qing Liu; Ming-Huang Hong; Zhen-Er Liao; Wei-Min Ye; Yi-Xin Zeng; Su-Mei Cao
Journal:  J Med Screen       Date:  2012-12-20       Impact factor: 2.136

8.  Lower mortality from nasopharyngeal cancer in The Netherlands since 1970 with differential incidence trends in histopathology.

Authors:  Melina Arnold; Maarten A Wildeman; Otto Visser; Henrike E Karim-Kos; Jaap M Middeldorp; Renske Fles; I Bing Tan; Jan Willem Coebergh
Journal:  Oral Oncol       Date:  2012-10-22       Impact factor: 5.337

9.  Epidemiology of nasopharyngeal carcinoma.

Authors:  Mimi C Yu; Jian-Min Yuan
Journal:  Semin Cancer Biol       Date:  2002-12       Impact factor: 15.707

10.  Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China.

Authors:  Wei-Hua Jia; Qi-Hong Huang; Jian Liao; Weimin Ye; Y Y Shugart; Qing Liu; Li-Zhen Chen; Yan-Hua Li; Xiao Lin; Fa-Lin Wen; Hans-Olov Adami; Yi Zeng; Yi-Xin Zeng
Journal:  BMC Cancer       Date:  2006-07-06       Impact factor: 4.430

View more
  29 in total

1.  Reduced expression of polymeric immunoglobulin receptor (pIgR) in nasopharyngeal carcinoma and its correlation with prognosis.

Authors:  Xuanchang Qi; Xuechang Li; Xiuxia Sun
Journal:  Tumour Biol       Date:  2016-02-24

2.  Temporal lobe injury after re-irradiation of locally recurrent nasopharyngeal carcinoma using intensity modulated radiotherapy: clinical characteristics and prognostic factors.

Authors:  Shuai Liu; Taixiang Lu; Chong Zhao; Jingxian Shen; Yunming Tian; Ying Guan; Lei Zeng; Weiwei Xiao; Shaomin Huang; Fei Han
Journal:  J Neurooncol       Date:  2014-07-02       Impact factor: 4.130

3.  Comprehensive profiling of EBV gene expression in nasopharyngeal carcinoma through paired-end transcriptome sequencing.

Authors:  Lijuan Hu; Zhirui Lin; Yanheng Wu; Juqin Dong; Bo Zhao; Yanbing Cheng; Peiyu Huang; Lihua Xu; Tianliang Xia; Dan Xiong; Hongbo Wang; Manzhi Li; Ling Guo; Elliott Kieff; Yixin Zeng; Qian Zhong; Musheng Zeng
Journal:  Front Med       Date:  2016-03-11       Impact factor: 4.592

4.  Incidence and mortality trends of nasopharynx cancer from 1990 to 2019 in China: an age-period-cohort analysis.

Authors:  Ruhai Bai; Jianzhong Sun; Yan Xu; Zhonghe Sun; Xiaoyan Zhao
Journal:  BMC Public Health       Date:  2022-07-15       Impact factor: 4.135

5.  The Epstein-Barr virus LMP1 interactome: biological implications and therapeutic targets.

Authors:  Mujeeb R Cheerathodi; David G Meckes
Journal:  Future Virol       Date:  2018-12-03       Impact factor: 1.831

6.  Epstein-Barr virus infection induces indoleamine 2,3-dioxygenase expression in human monocyte-derived macrophages through p38/mitogen-activated protein kinase and NF-κB pathways: impairment in T cell functions.

Authors:  Wan-li Liu; Yue-hao Lin; Han Xiao; Shan Xing; Hao Chen; Pei-dong Chi; Ge Zhang
Journal:  J Virol       Date:  2014-04-02       Impact factor: 5.103

7.  Incidence Trends and Geographical Distribution of Nasopharyngeal Carcinoma in Iran.

Authors:  Ali Safavi-Naini; Nasim Raad; Jahangir Ghorbani; Samira Chaibakhsh; Rashid Ramezani-Daryasar
Journal:  Iran J Cancer Prev       Date:  2015 Jan-Feb

8.  Is Hemoglobin Level in Patients with Nasopharyngeal Carcinoma Still a Significant Prognostic Factor in the Era of Intensity-Modulated Radiotherapy Technology?

Authors:  Shan-Shan Guo; Lin-Quan Tang; Qiu-Yan Chen; Lu Zhang; Li-Ting Liu; Pei-Yu Huang; Ka-Jia Cao; Ling Guo; Hao-Yuan Mo; Xiang Guo; Ming-Huang Hong; Mu-Sheng Zeng; Chao-Nan Qian; Hai-Qiang Mai
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

Review 9.  CCL27 Signaling in the Tumor Microenvironment.

Authors:  Miguel Martínez-Rodríguez; Carlos Monteagudo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Prognostic Nomogram for Patients with Nasopharyngeal Carcinoma after Intensity-Modulated Radiotherapy.

Authors:  Shixiu Wu; Bing Xia; Fei Han; Ruifei Xie; Tao Song; Lixia Lu; Wei Yu; Xiaowu Deng; Qiancheng He; Cong Zhao; Conghua Xie
Journal:  PLoS One       Date:  2015-08-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.